CompanyVYGRNasdaqLexington, MA

Voyager Therapeutics

Voyager Therapeutics develops AAV gene therapies for neurological diseases including Alzheimer's, Friedreich's ataxia, Parkinson's, and ALS using its TRACER platform to optimize brain delivery via intravenous administration.

Stories only

SEC EDGAR ClinicalTrials.gov voyagertherapeutics.com

424B3Sep 25Latest SEC filing

Aug 13Latest story

August 2026

Voyager Therapeutics registers Phase 1 dose-escalation trial of VY1706 in early Alzheimer's disease

Aug 13Trial updateVoyager Therapeutics VY1706

Voyager reports Q2 2026 results, sets Q4 milestones for two Alzheimer's programs

Aug 6Quarterly updateVoyager Therapeutics VY1706